Dec 1, 2010
By:
Jill Wechsler
Republican gains in Congress create uncertainty for health reform, drug regulation, and biomedical research
|
Nov 1, 2010
By:
Jill Wechsler
PCORI is independent and transparent and likely to alter methods for assesssing the value of new therapies
|
Health reform requires detailed tracking and full disclosure of fees to docs for marketing and research
Oct 1, 2010
By:
Jill Wechsler
Health reform requires detailed tracking and full disclosure of fees to docs for marketing and research
|
Sep 1, 2010
By:
Jill Wechsler
FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development
|
Jul 1, 2010
By:
Jill Wechsler
Drug prices, doctor payments, and FDA regulatory decisions are candidates for expanded disclosure.
|
Jun 1, 2010
By:
Jill Wechsler
FDA and industry seek to ensure drug quality in a world complicated by global outsourcing and theft.
|
May 1, 2010
By:
Jill Wechsler
Under the new healthcare regime, pharma will ante up fees and rebates in return for expanded sales and safeguards.
|
Commissioner Hamburg aims to regain public confidence in FDA by bolstering its scientific expertise. All she needs is more money.
Apr 1, 2010
By:
Jill Wechsler
FDA Commissioner Margaret Hamburg looks to bolster the agency's scientific expertise.
|
Mar 1, 2010
By:
Jill Wechsler
FDA's new Sentinel System is going live, but the signals may be difficult to assess.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
